News archive.
Earlier AI news and analysis, kept for reference. Current coverage lives in News & Analysis.
MCP becomes the procurement question law firms can't avoid
Law firms have AI tools in production, but they're stuck moving context between siloed systems. The Model Context Protocol is becoming the standard that decides whether AI actually works.
Sivers and GlobalFoundries Partner on AI Data Center Optics
Sivers Semiconductors and GlobalFoundries announced collaboration on optical interconnect solutions for AI data centers. Details on performance gains and deployment timeline remain unclear.
Your spectrophotometer's accuracy matters for pharma QC—here's how to verify it
Pharmaceutical quality control depends on spectrophotometer accuracy to detect impurities and verify active ingredients. NIST standards and certified reference materials define what 'accurate' means—and why training matters as much as the instrument.
Aragen scales neuroblastoma mAb to commercial production in 9 months
Renaissance Pharma's Daretabart, an FDA Fast Track antibody, completed tech transfer to Aragen's Bengaluru facility. The facility can produce 60-70 batches annually and supports parallel bioreactor runs for faster clinical supply.
DSV and MDC partner to unlock brain-drug delivery startups
Deep Science Ventures and Medicines Discovery Catapult are backing new companies to solve blood-brain barrier delivery. Over 40% of the global population faces CNS diseases with no effective treatment path.
Melanoma vaccine cuts death risk 49%, brain cancer survival up 11 months
Moderna and MSD's intismeran reduced melanoma recurrence and death by half in a five-year Phase IIb trial. Dana-Farber's NeoVax extended glioblastoma survival to 36.9 months — but vaccine timing matters.
Elahere flops in platinum-sensitive ovarian cancer trial
AbbVie's folate receptor-targeted ADC failed to extend survival in the MIROVA trial, despite a higher response rate. The miss upends growth forecasts and opens the door to competitors.
Brinsupri hits $208M quarterly sales, faces Europe pricing delay
Insmed's first-to-market bronchiectasis drug crossed $208M in Q1 2026 revenue but delayed European launch over US drug pricing policy uncertainty. Here's why pulmonologists are watching the regional rollout.
Servier buys Edgewise muscular dystrophy unit for $2.65B
Servier will pay $1.55B upfront plus $1.1B in milestones to acquire Edgewise's rare neurology portfolio, including sevasemten for Becker and Duchenne muscular dystrophy. Deal closes Q3 2026.
BMS wins FDA fast-track review for adolescent heart drug Camzyos
FDA accepted Bristol Myers Squibb's application to expand Camzyos to teens aged 12-17 with obstructive hypertrophic cardiomyopathy. Decision expected September 2026.
China's new cell therapy rule splits biotech in two commercial paths
Order 818, effective May 1, 2026, creates a hospital-based route for personalized cell and gene therapies alongside traditional drug approval. What it means for Chinese startups, foreign companies, and where innovation stays.
Boston Lab Space Glut Hits 32.7% as Biopharma Clusters Shift
Boston's dominance in life sciences is cracking: 32.7% of lab space sits empty, job losses mount, and mid-cap biopharmas are buying manufacturing instead of leasing. Where growth is actually happening in 2026.